BioWorld

Oct. 15, 2003

Built To Last' Reata Taking Aim At Cancer, Neurological Diseases

Immune Response Adds Cash, Raises $12M For HIV Vaccines

Other News To Note

U.S. Patent Disclosures

CoTherix Acquires Schering's U.S. Rights For Ventavis, Raises $55M

The company formerly known as Exhale Therapeutics Inc. has acquired a new name, a new financing and new U.S. rights to a pulmonary hypertension product. (BioWorld Today) Read More

Dyax To Receive $35M Through Biotage Sale To Pyrosequencing

Today's news in brief

BioWorld

BioWorld briefs for Dec. 10, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Dec. 10, 2025.

Epigenetic technology could eliminate misfolded prion proteins

BioWorld Science

The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...

CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials

BioWorld

A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...

Brenig Therapeutics discovers new LRRK2 inhibitors

BioWorld Science

Brenig Therapeutics Inc. has described leucine-rich repeat kinase 2 (LRRK2; dardarin) and (LRRK2; dardarin) (G2019S mutant) inhibitors reported to be useful for...